Rosiglitazone Does Not Show Major Hidden Cardiotoxicity in Models of Ischemia/Reperfusion but Abolishes Ischemic Preconditioning-Induced Antiarrhythmic Effects in Rats In Vivo

• Main Authors: Bennet Y. Weber (Author), Gábor B. Brenner (Author), Bernadett Kiss (Author), Tamás G. Gergely (Author), Nabil V. Sayour (Author), Huimin Tian (Author), András Makkos (Author), Anikó Görbe (Author), Péter Ferdinandy (Author), Zoltán Giricz (Author)
• Format: Knjiga
• Izdano: MDPI AG, 2022-08-01T00:00:00Z.
• Teme: article
• Online dostop: Connect to this object online.

Clinical observations are highly inconsistent with the use of the antidiabetic rosiglitazone regarding its associated increased risk of myocardial infarction. This may be due to its hidden cardiotoxic properties that have only become evident during post-marketing studies. Therefore, we aimed to inve...